1. Bioorg Med Chem Lett. 2005 Sep 1;15(17):3853-6. doi:
10.1016/j.bmcl.2005.05.121.

Lead optimization of 4-(dimethylamino)quinazolines, potent and selective 
antagonists for the melanin-concentrating hormone receptor 1.

Kanuma K(1), Omodera K, Nishiguchi M, Funakoshi T, Chaki S, Semple G, Tran TA, 
Kramer B, Hsu D, Casper M, Thomsen B, Sekiguchi Y.

Author information:
(1)Medicinal Research Laboratories, Taisho Pharmaceutical Co. Ltd., 1-403 
Yoshino-cho, Kita-ku, Saitama, Saitama 331-9530, Japan.

The optimization of a series of 4-(dimethylamino)quinazoline antagonists of the 
melanin-concentrating hormone receptor 1 (MCH-R1) is described. The combination 
of the elaboration of both the linker portion and the terminal phenyl ring 
provided 
N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-3,4-difluorobenzamide 
hydrochloride 28 (ATC0175), which showed excellent antagonist activity at the 
MCH-R1 (IC50 = 3.4 nM) as well as good selectivity over the Y5 and the alpha2A 
receptors.

DOI: 10.1016/j.bmcl.2005.05.121
PMID: 16002290 [Indexed for MEDLINE]
